Literature DB >> 26683675

FDA approves first intranasal naloxone product.

Kate Traynor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26683675     DOI： 10.2146/news160002

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  3 in total

1.  Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Authors:  Kelly E Dunn; Frederick S Barrett; George E Bigelow
Journal:  Addict Behav       Date:  2018-03-28       Impact factor: 3.913

Review 2.  Misuse of Novel Synthetic Opioids: A Deadly New Trend.

Authors:  Matthew P Prekupec; Peter A Mansky; Michael H Baumann
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

3.  Randomized controlled trial of a computerized opioid overdose education intervention.

Authors:  Kelly E Dunn; Claudia Yepez-Laubach; Paul A Nuzzo; Michael Fingerhood; Anne Kelly; Suzan Berman; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2017-04-01       Impact factor: 4.492
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.